Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson is weighing a sale of its DePuy Synthes orthopedics division that could fetch more than $20 billion, according to a source familiar with the situation, speaking to Reuters on Thursday. The company hasn’t commented yet. This potential sale marks a pivot from J&J’s previously outlined plan to spin off DePuy Synthes over the next 18 to 24 months. CFO Joe Wolk previously indicated no major updates would come before mid-2026. DePuy pulled in $9.3 billion in sales for 2025 and has faced thousands of hip implant lawsuits, Reuters noted.

Johnson & Johnson stock price holds near $238 after-hours as Supreme Court talc case move hits

Johnson & Johnson stock price holds near $238 after-hours as Supreme Court talc case move hits

Johnson & Johnson shares jumped about 1.4% Thursday, then held steady after hours. The move came as the company asked the U.S. Supreme Court to weigh in on whether a shareholder lawsuit accusing it of misleading statements about talc safety can move forward as a class action. The petition seeks clarification on the court’s 2021 Goldman Sachs ruling, focusing on how “price impact” — whether alleged falsehoods affected stock prices — factors into certifying investor groups. JNJ last changed hands at $237.79, after trading between $233.33 and $240.00 during regular hours.
1 2 3 4 9